CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

Vaccine

Volumn 26, Issue 32, 2008, Pages 4062-4072

  Liu, Jun ^a   Yu, Qigui ^a   Stone, Geoffrey W ^a   Yue, Feng Yun ^a   Ngai, Nicholas ^a   Jones, R Brad ^a   Kornbluth, Richard S ^b   Ostrowski, Mario A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

AIDS; Canarypox vector; Cytotoxic T cell

Indexed keywords

CD40 LIGAND; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 7 RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANARYPOX VIRUS; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; EX VIVO STUDY; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; APOPTOSIS; CANARYPOX VIRUS; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; VIRAL VACCINES;

EID: 47149112188     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.018     Document Type: Article

References (63)

1. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 6 December (12) (2006) 930-939
2. Johnston M.I., and Fauci A.S. An HIV vaccine-evolving concepts. N Engl J Med 356 May (20) (2007) 2073-2081
3. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93 October (21) (1996) 11341-11348
4. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 April (5) (1996) 428-434
5. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 May (1) (1992) 217-232
6. Cox W.I., Tartaglia J., and Paoletti E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 195 August (2) (1993) 845-850
7. Pitisuttithum P. HIV-1 prophylactic vaccine trials in Thailand. Curr HIV Res 3 January (1) (2005) 17-30
8. Marovich M.A. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev Vaccines 3 August (4 Suppl.) (2004) S99-S104
9. de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22 January (5/6) (2004) 704-713
10. Liniger M., Zuniga A., and Naim H.Y. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6 April (2) (2007) 255-266
11. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 177 May (5) (1998) 1230-1246
12. Cleghorn F., Pape J.W., Schechter M., Bartholomew C., Sanchez J., Jack N., et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr 46 October (2) (2007) 222-230
13. Thongcharoen P., Suriyanon V., Paris R.M., Khamboonruang C., de Souza M.S., Ratto-Kim S., et al. A phase 1/2 comparative vaccine trial of the safety: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr (2007)
14. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192 October (7) (2005) 1249-1259
15. Watts T.H. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23 (2005) 23-68
16. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 22 (2004) 307-328
17. Sugamura K., Ishii N., and Weinberg A.D. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 4 January (6) (2004) 420-431
18. Castellino F., and Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 24 (2006) 519-540
19. Bishop G.A., and Hostager B.S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev 14 June-August (3/4) (2003) 297-309
20. Lefrancois L., Altman J.D., Williams K., and Olson S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J Immunol 164 January (2) (2000) 725-732
21. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., and Heath W.R. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 June (6684) (1998) 478-480
22. Ridge J.P., Di Rosa F., and Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 June (6684) (1998) 474-478
23. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 June (6684) (1998) 480-483
24. Barr T.A., Carlring J., and Heath A.W. Co-stimulatory agonists as immunological adjuvants. Vaccine 24 April (17) (2006) 3399-3407
25. Yu Q., Yue F.Y., Gu X.X., Schwartz H., Kovacs C.M., and Ostrowski M.A. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition. J Immunol 176 February (4) (2006) 2486-2495
26. Yu Q., Gu J.X., Kovacs C., Freedman J., Thomas E.K., and Ostrowski M.A. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 170 February (4) (2003) 1797-1805
27. Ostrowski M.A., Justement S.J., Ehler L., Mizell S.B., Lui S., Mican J., et al. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses. J Immunol 165 December (11) (2000) 6133-6141
28. Fang Z.Y., Kuli-Zade I., and Spearman P. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis 180 October (4) (1999) 1122-1132
29. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339 June (8807) (1992) 1429-1432
30. Ostrowski M.A., Justement S.J., Ehler L., Mizell S.B., Lui S., Mican J., et al. The role of CD4(+) T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8(+) T cell responses. J Immunol 165 11 (2000) 6133-6141
31. Stone G.W., Barzee S., Snarsky V., Kee K., Spina C.A., Yu X.F., et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80 February (4) (2006) 1762-1772
32. Mata M., Travers P.J., Liu Q., Frankel F.R., and Paterson Y. The MHC class I-restricted immune response to HIV-gag in BALB/c mice selects a single epitope that does not have a predictable MHC-binding motif and binds to Kd through interactions between a glutamine at P3 and pocket D. J Immunol 161 September (6) (1998) 2985-2993
33. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107 June (12) (2006) 4781-4789
34. Almeida J.R., Price D.A., Papagno L., Arkoub Z.A., Sauce D., Bornstein E., et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204 October (10) (2007) 2473-2485
35. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204 June (6) (2007) 1405-1416
36. Kaech S.M., Tan J.T., Wherry E.J., Konieczny B.T., Surh C.D., and Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4 December (12) (2003) 1191-1198
37. Caux C., Massacrier C., Vanbervliet B., Dubois B., Van Kooten C., Durand I., et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180 October (4) (1994) 1263-1272
38. Mackey M.F., Gunn J.R., Maliszewsky C., Kikutani H., Noelle R.J., and Barth Jr. R.J. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 161 September (5) (1998) 2094-2098
39. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 74 December (23) (2000) 11329-11338
40. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science (New York, NY) 318 October (5847) (2007) 28-29
41. Douek D.C., Kwong P.D., and Nabel G.J. The rational design of an AIDS vaccine. Cell 124 February (4) (2006) 677-681
42. Hanke T., McMichael A.J., and Dorrell L. Clinical experience with plasmid DNA and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 88 January (Pt 1) (2007) 1-12
43. Schoenly K.A., and Weiner D.B. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol 82 April (7) (2008) 3166-3180
44. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 77 August (16) (2003) 8729-8735
45. Kutzler M.A., Robinson T.M., Chattergoon M.A., Choo D.K., Choo A.Y., Choe P.Y., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 175 July (1) (2005) 112-123
46. Kwissa M., Amara R.R., Robinson H.L., Moss B., Alkan S., Jabbar A., et al. Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus. J Exp Med 204 October (11) (2007) 2733-2746
47. Harrison J.M., Bertram E.M., Boyle D.B., Coupar B.E., Ranasinghe C., and Ramshaw I.A. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 24 November (47/48) (2006) 6867-6874
48. Paoletti E., Tartaglia J., and Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 82 (1994) 65-69
49. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 167 December (11) (2001) 6330-6337
50. Havari E., Lennon-Dumenil A.M., Klein L., Neely D., Taylor J.A., McInerney M.F., et al. Expression of the B7.1 costimulatory molecule on pancreatic beta cells abrogates the requirement for CD4 T cells in the development of type 1 diabetes. J Immunol 173 July (2) (2004) 787-796
51. Bukczynski J., Wen T., Wang C., Christie N., Routy J.P., Boulassel M.R., et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol 175 November (10) (2005) 6378-6389
52. Kovarik J., Martinez X., Pihlgren M., Bozzotti P., Tao M.H., Kipps T.J., et al. Limitations of in vivo IL-12 supplementation strategies to induce Th1 early life responses to model viral and bacterial vaccine antigens. Virology 268 March (1) (2000) 122-131
53. Moore A.C., Kong W.P., Chakrabarti B.K., and Nabel G.J. Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice. J Virol 76 January (1) (2002) 243-250
54. Reali E., Canter D., Zeytin H., Schlom J., and Greiner J.W. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23 April (22) (2005) 2909-2921
55. Makedonas G., and Betts M.R. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 28 November (3) (2006) 209-219
56. MacLeod M., Kwakkenbos M.J., Crawford A., Brown S., Stockinger B., Schepers K., et al. CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med 203 April (4) (2006) 897-906
57. Gerloni M., Xiong S., Mukerjee S., Schoenberger S.P., Croft M., and Zanetti M. Functional cooperation between T helper cell determinants. Proc Natl Acad Sci USA 97 November (24) (2000) 13269-13274
58. Howland K.C., Ausubel L.J., London C.A., and Abbas A.K. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 164 May (9) (2000) 4465-4470
59. Ryan E.J., Harenberg A., and Burdin N. The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-gamma by natural killer (NK) cells enhancing Th1 polarization. Vaccine 25 April (17) (2007) 3380-3390
60. Yu Q., Jones B., Hu N., Chang H., Ahmad S., Liu J., et al. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 24 September (40/41) (2006) 6376-6391
61. Lane H.C., Depper J.M., Greene W.C., Whalen G., Waldmann T.A., and Fauci A.S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 313 2 (1985) 79-84
62. Hel Z., Venzon D., Poudyal M., Tsai W.P., Giuliani L., Woodward R., et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 6 October (10) (2000) 1140-1146
63. Jin X., Ramanathan Jr. M., Barsoum S., Deschenes G.R., Ba L., Binley J., et al. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 76 March (5) (2002) 2206-2216